Beijing Tong Ren Tang Chinese Medicine Company Limited provided earnings guidance for the year ended 31 December 2023. For the year, revenue of the Group is expected to decrease by 11% to 15% and the profit after tax of the Group is expected to decrease by 18% to 22%, for the year ended 31 December 2023 as compared to the corresponding period in 2022. The expected decrease in revenue and profit after tax of the Group for the year ended 31 December 2023 is mainly attributable to a deviation between the market actual conditions and demand after the pandemic from expectation, where some distributors in the mainland China were still off-loading the own products of the Group during 2023, which has affected the sales of the Group's own products in the mainland China.

The Company's management has taken a number of contingency measures instantly, including strengthening distribution channel building and marketing promotion etc., to optimize the marketing environment, thereby enhancing profitability of the Group.